BioBridgeX
Log inCompare quotes
CMC / Manufacturing

Stability Studies CDMOs

Free for buyersNeutral vendor of record
Quick answer

Stability studies measure how a drug substance or product changes over time under controlled temperature and humidity, setting shelf life, storage conditions, and the data behind your CMC filing. You need them once you have GMP material to support an IND, clinical batches, or a BLA/NDA. On BioBridgeX, buyers source and compare qualified stability-testing CDMOs under one contract.

Stability Studies CDMOs on BioBridgeX

We are qualifying and publishing Stability Studies CDMOs now. Tell us what you need and we will match you with vetted vendors, or list your organization to be among the first.

What is a stability study and when do you need it?

A stability study measures how your drug substance and drug product change over time once they sit in a vial, syringe, or blister at a defined temperature and humidity. The point is to answer three regulatory questions with real data: how long the product stays within specification (the shelf life or retest period), how it should be stored and labeled, and what packaging actually protects it. You put material on stability, pull samples at set time points, and test each pull against a stability-indicating method that can see degradation when it happens.

The work is governed by the ICH Q1 series, which most agencies have adopted. Q1A(R2) sets the core long-term, intermediate, and accelerated conditions, Q1B covers photostability, Q1C extends the approach to new dosage forms, Q1D allows bracketing and matrixing to reduce the number of samples, Q1E governs how you extrapolate a shelf life from the data, and Q1F sets the storage conditions for the climatic zones (the warmer, more humid Zone IVb matters if you plan to sell in those markets). The standard long-term condition for a room-temperature product is 25 degrees C and 60 percent relative humidity, with accelerated at 40 degrees C and 75 percent RH; refrigerated and frozen products carry their own conditions.

You need stability data at almost every gate. A first stability program supports the IND, where a few months of data is usually enough to justify dosing your clinical batch. Programs expand through Phase 2 and Phase 3 as batches scale, and the registration stability package behind a BLA or NDA typically rests on multiple primary batches with long-term data at submission and a commitment to keep the chambers running. Practically, you cannot release a clinical batch without an assigned use period, and you cannot file without a shelf life backed by real-time data, so stability tends to sit quietly on the critical path long before anyone is watching it.

What does a stability studies CDMO actually do?

A stability CDMO runs the protocol end to end: it designs the study against ICH, holds your samples in qualified and continuously monitored chambers, pulls and tests at each scheduled time point, trends the results, and issues the reports that go into your filing. Most of the real value is in the testing and the interpretation, not just the storage, so the analytical depth of the lab matters more than the size of its chamber farm.

The scope usually splits into a few recognizable pieces. Storage and pull management is the logistics spine. Forced degradation (stress testing under acid, base, oxidation, heat, and light) is what proves your assay is genuinely stability-indicating, because a method that cannot detect degradants is worthless on a stability study. Then there is the recurring analytical panel run at each pull, plus a set of specialized studies sponsors often forget to scope until late.

  • Protocol design and storage: study design to ICH Q1A through Q1F, bracketing and matrixing under Q1D, plus sample inventory and pulls from validated, alarmed chambers across long-term, intermediate, accelerated, refrigerated, and frozen conditions.
  • Forced degradation and method validation: acid, base, oxidative, thermal, and photolytic stress to demonstrate a stability-indicating method, mass balance, and degradant tracking, supporting method validation under ICH Q2.
  • The recurring analytical panel: assay and related substances by HPLC or UPLC, appearance, pH, water content (Karl Fischer), dissolution, and for biologics the higher-order panel (SEC and CEX for aggregation and charge variants, sub-visible particles, potency, and capillary electrophoresis).
  • Photostability per ICH Q1B: confirmatory exposure to ICH light conditions to set protective packaging and labeling.
  • Container-closure and in-use studies: testing the product in its final primary pack, plus in-use stability after first opening or reconstitution to support the in-use shelf life on the label.
  • Excursion and transport studies: short-term thermal excursions, freeze-thaw cycling, and temperature mapping to support shipping lanes and cold-chain claims.

How do you choose a stability studies CDMO?

The first filter is modality fit, because the analytical work is completely different across product types. A lab that runs flawless small-molecule HPLC stability is the wrong choice for a monoclonal antibody, where the live questions are aggregation, charge heterogeneity, and potency, and it is further still from a cell or gene therapy product with its own potency and identity challenges. Match the CDMO to a lab that runs your specific stability-indicating methods every week, not one stretching to win the work.

After modality, the practical questions decide it. Confirm GMP status and a clean inspection history from the agencies you plan to file with, since a stability report only counts in a submission if the lab that produced it holds up to an audit. Check real chamber capacity and that the conditions you need (including ICH Zone IVb if you sell into warm, humid markets, and any refrigerated or frozen conditions) are available now, not in six months. Confirm the lab can run, or transfer and validate, your stability-indicating methods, because a chamber slot is worthless without the analytics behind it.

Use a short checklist when you compare quotes side by side:

  • Quality and GxP status: current GMP, a recent FDA, EMA, or PMDA inspection history without serious findings, and data integrity practices you can audit.
  • Capacity and lead time: chamber availability across the exact ICH conditions you need, realistic pull-and-report turnaround, and what historically causes slippage on a multi-year program.
  • Modality and indication fit: documented stability-indicating methods for your product type (small molecule, antibody, ADC, peptide or oligonucleotide, viral vector, mRNA or LNP, cell therapy), with the right higher-order analytics for biologics.
  • Region and regulatory track record: experience supporting the agencies you will file with, the climatic zones of your target markets, and a history of stability data surviving review.
  • Data quality and reporting: stability-indicating method validation, mass balance and degradant tracking, trended results, and clear out-of-specification and out-of-trend handling.
  • IP and confidentiality: clear ownership of methods and data, secure sample chain-of-custody, and confidentiality terms that protect an undisclosed program.

Frequently asked questions

What ICH guidelines govern stability studies?
The ICH Q1 series. Q1A(R2) sets the core long-term, intermediate, and accelerated conditions; Q1B covers photostability; Q1C extends the approach to new dosage forms; Q1D allows bracketing and matrixing to cut the number of samples; Q1E governs how you extrapolate shelf life from the data; and Q1F sets storage conditions for the climatic zones, including the warm, humid Zone IVb. A stability-indicating method is also validated to ICH Q2. Most agencies (FDA, EMA, PMDA) have adopted these, so a CDMO running your program should design it against Q1 from the start.
What is the difference between real-time, accelerated, and intermediate stability testing?
Real-time (long-term) testing holds product at its intended storage condition, commonly 25 degrees C and 60 percent relative humidity for a room-temperature product, and this is the data that ultimately establishes shelf life. Accelerated testing at 40 degrees C and 75 percent RH stresses the product to predict stability and support an early, provisional shelf life and short-term excursions. Intermediate (30 degrees C and 65 percent RH) is triggered when significant change shows up under accelerated conditions. You cannot replace real-time data with accelerated alone; the long-term chambers have to keep running.
How long does a stability study take?
It runs in the background for as long as your claimed shelf life, so plan in months to years rather than weeks. Accelerated data (typically six months) can support an early provisional shelf life, but a registration program needs long-term data covering enough of the proposed shelf life at submission, with a commitment to continue the chambers and report through expiry. Because real-time data accrues at its own pace, you start stability early and let it run; it is one of the first things to schedule and one of the last to finish.
What is a stability-indicating method and why does forced degradation matter?
A stability-indicating method is an analytical method that can accurately measure the active ingredient while detecting and resolving its degradation products, so it actually sees the product changing. Forced degradation (deliberately stressing samples with acid, base, oxidation, heat, and light per ICH Q1B) is how you prove the method is stability-indicating: it generates degradants and shows the assay separates and quantifies them with acceptable mass balance. Without this work, a clean stability result is meaningless, because the method may simply be blind to the degradation that is occurring.
Do stability studies need to be run under GMP, and do biologics need a different program?
Any stability data you cite in a filing, and the testing behind a released clinical or commercial batch, must come from a GMP lab using validated, stability-indicating methods; early development stability (formulation screening, method-developing forced degradation) can run non-GMP to make decisions cheaply. Modality also reshapes the program. A small molecule leans on HPLC assay and related substances, while a monoclonal antibody adds aggregation (SEC), charge variants (CEX or capillary electrophoresis), sub-visible particles, and potency, often at refrigerated or frozen conditions. Cell and gene therapies carry their own potency and identity challenges. Match the CDMO to a lab that runs your modality's methods routinely.
Is sourcing a stability studies CDMO on BioBridgeX free for buyers?
Yes. BioBridgeX is free for buyers, with no platform fee and no demo wall. A flat 2 percent sits on vendor quotes, disclosed up front and owed only once the vendor is paid, and that is the only fee in the model. Because BioBridgeX is a neutral vendor of record that runs no lab of its own, there is no incentive to steer you toward a particular CDMO. When stability sits alongside other CMC work, you sign one contract and receive one PO and one consolidated invoice across every vendor you use.

Source Stability Studies with one contract

Compare transparent quotes from qualified Stability Studies CDMOs, then contract once. Free for buyers.

Compare quotes